Journal ArticleOPEN ACCESS

Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non–small cell lung cancer?

Cancer (2018) 124(24) 4592-4596
DOI: 10.1002/cncr.31681
10Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Goldberg, S. B., & Herbst, R. S. (2018). Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non–small cell lung cancer? Cancer, 124(24), 4592–4596. https://doi.org/10.1002/cncr.31681

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free